Lenalidomid Al (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. The result is reduced growth of malignant plasma cells, enhanced immune‑mediated tumor killing, and inhibition of new blood‑vessel formation.

The dose of Lenalidomid Al is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Dosing regimens are established in clinical guidelines and must be followed as directed by a qualified healthcare professional.

Lenalidomid Al is classified as Pregnancy Category X because it is known to cause severe fetal harm and birth defects. It must not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. The drug is also not recommended while breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomid Al. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, and stronger anti‑angiogenic activity. Both drugs share a similar mechanism of cereblon binding, but lenalidomide is often preferred for its potency and reduced toxicity in modern treatment protocols.

Lenalidomid Al should be stored at room temperature, preferably below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and excessive heat. Keep the medication out of reach of children and do not use it after the expiration date printed on the label.

Lenalidomid Al is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water. Patients should follow any specific timing instructions provided by their healthcare professional, such as taking the dose on certain days of a treatment cycle.

The most serious risks include thromboembolic events (blood clots), severe neutropenia or leukopenia that can lead to infections, secondary primary malignancies, and teratogenic effects that can cause birth defects. Patients should be monitored regularly for signs of clotting, low blood counts, liver function changes, and any unexpected skin reactions.

Lenalidomid Al should not be used by pregnant women or anyone who may become pregnant without effective contraception. Patients with known hypersensitivity to lenalidomide or its excipients, those with severe renal impairment (creatinine clearance < 30 mL/min) without dose adjustment, and individuals with uncontrolled active infections should avoid the medication.